MedTrace Logo

A Phase I Study in Healthy Volunteers and Parkinson's Disease (PD) Patients.

NCT07630545 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 106

Last updated 2026-07-29

No results posted yet for this study

Summary

The goal of this trial is to learn if MTX325 can be developed as a potential disease-modifying treatment for Parkinson's Disease. Parts 1-4 complete, Part 5 (multiple doses in patients with Parkinson's Disease) in progress.

Conditions

  • Parkinson's Disease (PD)
  • Mild to Moderate Parkinson's Disease
  • Early Stage Parkinson's Disease

Interventions

DRUG

MTX325

MTX325

OTHER

Placebo

Placebo

Sponsors & Collaborators

  • Michael J. Fox Foundation for Parkinson's Research

    collaborator OTHER

  • Parkinson's UK

    collaborator OTHER

  • Mission Therapeutics

    lead NETWORK

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-11-30
Primary Completion
2027-06-30
Completion
2027-12-27

Countries

  • Australia
  • France
  • Germany
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07630545 on ClinicalTrials.gov